Humana (HUM) Stock May Still Offer Value After Medicare Advantage Exits
Humana stock has delivered a 45.4% return over the past year, yet the broader valuation checks paint a more cautious picture, so investors are weighing a strong share price run against a mixed read on value.
- Over the last 12 months Humana has returned 45.4%, which puts recent momentum firmly on the side of existing shareholders.
- The planned exit from additional lower return Medicare Advantage plans may support profitability over time. However, any misstep in reshaping that portfolio could pressure future earnings and investor confidence in the valuation.
- Humana screens as undervalued on some traditional multiples, but with a 3 out of 6 value checks passing, the overall picture is mixed rather than a clear bargain.
For investors, the debate is whether Humana's strong recent share price performance still leaves enough valuation support to justify taking or adding to a position at current levels.
Does Humana Look Undervalued on Earnings?
The P/E ratio is a useful way to judge what investors are currently willing to pay for each dollar of Humana earnings. Humana trades on a P/E of 34.5x, which is above both the healthcare industry average of 25.4x and the peer group average of 28.9x. On simple comparisons, the stock carries a premium to much of the sector.
A fair P/E multiple that adjusts for Humana size, risk profile and business mix is estimated at 46.2x. This is meaningfully higher than where the stock trades today and it points to undervaluation on this framework even though the headline P/E looks rich against the sector. Despite recent headlines about exiting lower return Medicare Advantage plans and the share price strength over the last year, the current P/E still sits below this more tailored fair value marker.
On the P/E multiple, Humana stock screens as undervalued relative to the level suggested by its fair ratio.
See what the numbers say about this price — find out in our valuation breakdown.
The Humana Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Humana valuation puzzle leaves off and explain what would need to happen to Humana's growth, margins and earnings for the stock to be worth materially more or less than it is today. Each narrative links a specific fair value estimate to a clear story about Humana's potential catalysts and risks, so you can track over time which version of events is taking shape.
One of the top community narratives on Humana: 73% overvalued
"For Humana, this means that operational precision matters more than ever, and systems must not only be efficient, but auditable and consistent with CMS guidance..."
Read one of the top narratives on Humana
Do you think there's more to the story for Humana? Head over to our Community to see what others are saying!
The Bottom Line
Humana screens as undervalued on its tailored P/E multiple, yet the broader valuation checks are only mixed, so the stock does not come through as a straightforward bargain. The key question is whether the shift away from lower return Medicare Advantage plans can protect margins without unsettling growth and earnings quality. If execution on that portfolio reshaping holds together, the current discount on the fair ratio could look appealing. If it does not, the apparent value may simply reflect the risk that Humana's profitability profile proves harder to sustain than optimists expect.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com